Gordon A. Dale

Gordon A. Dale

Auto-generated profile, based on publicly available information

Gordon A. Dale

The Ragon Institute of Mass General Brigham, MIT, and Harvard 1 Batista Lab Cambridge, MA

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 January 2014 in Journal of Cerebral Blood Flow & Metabolism
Verified
Journal Article
Open access
SAStephanie E Adamczak
Stephanie E Adamczak
Juan Pablo de Rivero VaccariJuan Pablo de Rivero Vaccari
Juan Pablo de Rivero Vaccari
GDGordon Dale
Gordon Dale
FBFrank J Brand
Frank J Brand
DNDoris Nonner
Doris Nonner
Robert W KeaneRobert W Keane
Robert W Keane
The central nervous system (CNS) is an active participant in the innate immune response to infection and injury. In these studies, we show embryonic cortical neurons express a functional, deoxyribonucleic acid (DNA)-responsive, absent in melanoma 2 (AIM2) inflammasome that activates caspase-1. Neurons undergo pyroptosis, a proinflammatory cell death mechanism characterized by the following: (a) oligomerization of apoptosis-associated speck-like protein containing a caspase recruitment domain (ASC); (b) caspase-1 dependency; (c) formation of discrete pores in the plasma membrane; and (d) release of the inflammatory cytokine interleukin-1 β (IL-1 β). Probenecid and Brilliant Blue FCF, inhibitors of the pannexin1 channel, prevent AIM2 inflammasome-mediated cell death, identifying pannexin1 as a cell death effector during pyroptosis and probenecid as a novel pyroptosis inhibitor. Furthermore, we show activation of the AIM2 inflammasome in neurons by cerebrospinal fluid (CSF) from traumatic brain injury (TBI) patients and oligomerization of ASC. These findings suggest neuronal pyroptosis is an important cell death mechanism during CNS infection and injury that may be attenuated by probenecid.

1 December 2012 in Journal of Neurosurgery
Verified
Journal Article
Closed access
PDF file
SAStephanie Adamczak
Stephanie Adamczak
GDGordon Dale
Gordon Dale
Juan Pablo de Rivero VaccariJuan Pablo de Rivero Vaccari
Juan Pablo de Rivero Vaccari
MBM. Ross Bullock
M. Ross Bullock
WDW. Dalton Dietrich
W. Dalton Dietrich
Robert W KeaneRobert W Keane
Robert W Keane
Object: Traumatic brain injury (TBI), the third most common CNS pathology, plagues 5.3 million Americans with permanent TBI-related disabilities. To evaluate injury severity and prognosis, physicians rely on clinical variables. Here, the authors seek objective, biochemical markers reflecting molecular injury mechanisms specific to the CNS as more accurate measurements of injury severity and outcome. One such secondary injury mechanism, the innate immune response, is regulated by the inflammasome, a molecular platform that activates caspase-1 and interleukin-1β. Methods: The authors investigated whether inflammasome components were present in the CSF of 23 patients with TBI and whether levels of inflammasome components correlate with outcome. The authors performed an immunoblot analysis of CSF samples from patients who suffered TBI and nontrauma controls and assessed the outcomes 5 months postinjury by using the Glasgow Outcome Scale. Data were analyzed using Mann-Whitney U-tests and linear regression analysis. Results: Patients with severe or moderate cranial trauma exhibited significantly higher CSF levels of the inflammasome proteins ASC, caspase-1, and NALP-1 than nontrauma controls (p < 0.0001, p = 0.0029, and p = 0.0202, respectively). Expression of each protein correlated significantly with the Glasgow Outcome Scale score at 5 months postinjury (p < 0.05). ASC, caspase-1, and NALP-1 were significantly higher in the CSF of patients with unfavorable outcomes, including death and severe disability (p < 0.0001). Conclusions: NALP-1 inflammasome proteins are potential biomarkers to assess TBI severity, outcome, and the secondary injury mechanisms impeding recovery, serving as adjuncts to clinical predictors.

1 December 2011 in BMC Neuroscience
Verified
Journal Article
Open access
PDF file
LMLana J Mawhinney
Lana J Mawhinney
Juan Pablo de Rivero VaccariJuan Pablo de Rivero Vaccari
Juan Pablo de Rivero Vaccari
GDGordon A Dale
Gordon A Dale
RKRobert W Keane
Robert W Keane
HBHelen M. Bramlett
Helen M. Bramlett
Background: Members of the mammalian nucleotide binding domain, leucine-rich repeat (LRR)-containing receptor (NLR) family of proteins are key modulators of innate immunity regulating inflammation. Our previous work has shown that among the members of this family, NLRP1/NALP1, present in neurons, plays a crucial role in inflammasome formation and the production of the inflammatory cytokines interleukin (IL) -1β and IL-18 after various types of central nervous system injury.Results: We investigated whether age-related cognitive decline may involve a heightened inflammatory response associated with activation of the NLRP1 inflammasome in the hippocampus. Young (3 months) and aged (18 months) male Fischer 344 rats were tested in a spatial acquisition task via Morris water maze. Following behavioral testing, hippocampal lysates were assayed for expression of NLRP1 inflammasome components and inflammatory cytokines. Hippocampal lysates from aged rats showed significantly higher levels of NLRP1 inflammasome constituents, caspase-1, caspase-11, the purinergic receptor P2X7, pannexin-1 and X-linked inhibitor of apoptosis (XIAP) than lysates from younger animals. Following treatment with probenecid, an inhibitor or pannexin-1, aged animals demonstrated reduction in inflammasome activation and improvement in spatial learning performance.Conclusions: Our behavioral findings are consistent with increases in IL-1β and IL-18 that have been previously shown to correlate with spatial learning deficits. Probenecid reduced activated caspase-1 and ameliorated spatial learning deficits in aged rats. Thus, aging processes stimulate activation of the NLRP1 inflammasome and secretion of IL-1β and IL-18 that may contribute to age-related cognitive decline in the growing elderly population. Moreover, probenecid may be potentially useful as a therapy to improve cognitive outcomes in the aging population.

17 May 2024 in Science
Verified
Journal Article
Closed access
ZXZhenfei Xie
Zhenfei Xie
YLYing-Cing Lin
Ying-Cing Lin
JSJon M. Steichen
Jon M. Steichen
GOGabriel Ozorowski
Gabriel Ozorowski
SKSven Kratochvil
Sven Kratochvil
FBFacundo D. Batista
Facundo D. Batista
Germline-targeting (GT) HIV vaccine strategies are predicated on deriving broadly neutralizing antibodies (bnAbs) through multiple boost immunogens. However, as the recruitment of memory B cells (MBCs) to germinal centers (GCs) is inefficient and may be derailed by serum antibody–induced epitope masking, driving further B cell receptor (BCR) modification in GC-experienced B cells after boosting poses a challenge. Using humanized immunoglobulin knockin mice, we found that GT protein trimer immunogen N332-GT5 could prime inferred-germline precursors to the V3-glycan–targeted bnAb BG18 and that B cells primed by N332-GT5 were effectively boosted by either of two novel protein immunogens designed to have minimum cross-reactivity with the off-target V1-binding responses. The delivery of the prime and boost immunogens as messenger RNA lipid nanoparticles (mRNA-LNPs) generated long-lasting GCs, somatic hypermutation, and affinity maturation and may be an effective tool in HIV vaccine development.

1 September 2019 in The Journal of Immunology
Verified
Journal Article
Open access
PDF file
GDGordon A Dale
Gordon A Dale
DWDaniel J. Wilkins
Daniel J. Wilkins
CBCaitlin D. Bohannon
Caitlin D. Bohannon
DDDario Dilernia
Dario Dilernia
EHEric Hunter
Eric Hunter
JJJoshy Jacob
Joshy Jacob
Somatic hypermutation generates a myriad of Ab mutants in Ag-specific B cells, from which high-affinity mutants are selected. Chickens, sheep, and rabbits use nontemplated point mutations and templated mutations via gene conversion to diversify their expressed Ig loci, whereas mice and humans rely solely on untemplated somatic point mutations. In this study, we demonstrate that, in addition to untemplated point mutations, templated mutagenesis readily occurs at the murine and human Ig loci. We provide two distinct lines of evidence that are not explained by the Neuberger model of somatic hypermutation: 1) across multiple data sets there is significant linkage disequilibrium between individual mutations, especially among close mutations, and 2) among those mutations, those <8 bp apart are significantly more likely to match microhomologous regions in the IgHV repertoire than predicted by the mutation profiles of somatic hypermutation. Together, this supports the role of templated mutagenesis during somatic diversification of Ag-activated B cells.

1 June 2014 in Immunotherapy
Verified
Journal Article
Closed access
JPJaina M Patel
Jaina M Patel
GDGordon A Dale
Gordon A Dale
VVVincent F Vartabedian
Vincent F Vartabedian
PDPaulami Dey
Paulami Dey
PSPeriasamy Selvaraj
Periasamy Selvaraj
Evaluation of: Davila ML, Riviere I, Wang X et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci. Transl. Med. 6(224), 224ra25 (2014). Re...